Results 231 to 240 of about 5,379,197 (286)

Clinical outcomes of lenalidomide, bortezomib, and dexamethasone in multiple myeloma patients. [PDF]

Am J Transl Res
Yu L, Ren L, Hou Z, Yang Y, Zhang K.
europepmc   +1 more source

Next‐generation proteomics improves lung cancer risk prediction

Molecular Oncology, EarlyView.
This is one of very few studies that used prediagnostic blood samples from participants of two large population‐based cohorts. We identified, evaluated, and validated an innovative protein marker model that outperformed an established risk prediction model and criteria employed by low‐dose computed tomography in lung cancer screening trials.
Megha Bhardwaj, Clara Frick, Ben Schöttker, Bernd Holleczek, Hermann Brenner   +4 more
wiley   +1 more source

Clinical Outcomes of Adult Patients With Newly Diagnosed Mixed Phenotype Acute Leukemia. [PDF]

JCO Precis Oncol
Goulart H, Ravandi F, Short NJ, Jain N, Daver N, Kadia TM, DiNardo C, Borthakur G, Takahashi K, Pemmaraju N, Haddad FG, Montalban Bravo G, Alvarado Y, Issa GC, Bataller A, Pierce S, Loghavi S, Tang G, Wang SA, Thakral B, Shpall E, Champlin R, Khouri I, Kebriaei P, Garcia-Manero G, Sasaki K, Jabbour EJ, Senapati J.   +27 more
europepmc   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

Molecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak, Karolina Pytlak, Sandra Jaworowska, Bogusz Kulawiak, Piotr Bednarczyk   +4 more
wiley   +1 more source

Helmet Therapy for Deformational Plagiocephaly: Clinical Outcomes and Considerations. [PDF]

Children (Basel)
Ching SY, Wong OC, Chau WW, Hung AL, Lam TP, Lau AY.   +5 more
europepmc   +1 more source

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Is the Six-Minute Walk Test the Key to Boost Postoperative Clinical Outcomes in Cardiac Surgery? [PDF]

Braz J Cardiovasc Surg
Rocco IS, Gomes WJ, Bublitz C, Sião ARM, Hossne Junior NA, Guizilini S.   +5 more
europepmc   +1 more source